Uses of Xibtosan

Xibtosan has the main ingredient Etoricoxib, which belongs to the group of non-steroidal anti-inflammatory drugs (NSAIDs). Xibtosan medicine is commonly used in the treatment of pain relief and musculoskeletal pain relief, menstrual pain... Essential information such as composition, indications, contraindications, usage and side effects of the drug Xibtosan will help patients achieve the best treatment results.

Xibtosan medicine is made in the form of tablets, with the main ingredients including:
Active ingredients: Etoricoxib 90mg. Excipients: Just enough for 1 tablet of 90mg. Pharmacodynamics:
Etoricoxib tablets belong to the group of non-steroidal anti-inflammatory drugs (NSAIDs). Etoricoxib inhibits the synthesis of prostaglandins through selective inhibition of Cyclooxygenase-2 (COX-2), a reactant with inflammatory agents and has a major role in the synthesis of mediators of Prostanoic acid causes pain, inflammation, and fever. Selective inhibition of Cyclooxygenase-2 (COX-2) by administration of Etoricoxib can reduce the signs and symptoms of inflammation, pain, and fever, and reduce gastrointestinal toxicity without adverse effects on function. of platelets.

Xibtosan is a prescription drug used to treat adults or children over 16 years old in the following cases:
Symptoms of acute and chronic osteoarthritis, ankylosing spondylitis, rheumatoid arthritis. The patient has acute rheumatoid arthritis. Pain after dental or other surgery. Dysmenorrhea . Relief of acute and chronic pain in other diseases.

Allergy to any ingredient of Xibtosan medicine. History of allergy to other medicines containing Etoricoxib. History of allergy to other non-steroidal anti-inflammatory drugs (NSAIDs). People with peptic ulcer or gastrointestinal bleeding, gastroenteritis. People with a history of or are suffering from bronchospasm, nasal polyps, neurovascular edema, acute rhinitis. People with congestive heart failure NYHA II-IV. People with ischemic heart disease, cerebrovascular disease or peripheral artery disease. People with severe liver failure (Child-Pugh ≥10 or blood albumin <25g/l). Patients with severe renal impairment (creatinine clearance <30ml/min). People with hypertension with blood pressure readings usually above 140/90 and not controlled with antihypertensive drugs. Children under 16 years old. Pregnant or lactating women.

Dosage:
Osteoarthritis: The recommended dose is 30mg/time x 1 time/day. Increase the oral dose to 60mg once a day if the patient does not respond to the recommended dose. Rheumatoid arthritis: The recommended dose is 60mg/time x 1 time/day. Increase the oral dose to 90mg once a day if the patient does not respond to the recommended dose. Ankylosing spondylitis: The recommended dose is 60mg/time x 1 time/day. Increase the oral dose to 90mg once a day if the patient does not respond to the recommended dose. Pain after dental surgery: The recommended dose is 90mg/time x 1 time/day. Maximum treatment for 3 days. Acute dysentery: The recommended dose should not exceed 120mg/day. Maximum treatment for 8 days. In patients with hepatic impairment, the dose should be adjusted based on the Child-Pugh scale: Child-Pugh 5 - 6: Take no more than 60 mg/time/day. Child-Pugh 7 - 9: Take no more than 30 mg/time/day. Child-Pugh ≥ 10: Not recommended. Patients with renal failure based on Creatinine clearance (CrCl) CrCl ≥ 30 ml/min: No dose adjustment is required. CrCl < 30 ml/min: Not recommended Note: Xibtosan can be used before or after meals.

Side effects encountered when using Xibtosan
Using Xibtosan in high doses and for a long time may encounter the following unwanted side effects:
Common: Superficial osteoarthritis, edema due to fluid retention. Dizziness, headache, palpitations, arrhythmia, hypertension, bronchospasm. Abdominal pain, constipation, flatulence, gastritis, heartburn, gastroesophageal reflux, diarrhea, gastrointestinal disturbances, epigastric discomfort, nausea, vomiting, esophagitis, mouth ulcers, elevated liver enzymes ALT , AST. Bruising, weakness, fatigue, flu-like symptoms. Uncommon: Anemia, lymphocytopenia, thrombocytopenia. Hypersensitivity reactions such as urticaria, redness, itching. Weight gain, increase or decrease in appetite. Anxiety, depression, reduced mental acuity, hallucinations, taste disturbances, insomnia, paresthesias, decreased sensation, somnolence. Blurred vision, conjunctivitis, tinnitus, dizziness. Atrial fibrillation, tachycardia, congestive heart failure, uncharacterized ECG changes, angina pectoris, myocardial infarction, facial flushing, cerebrovascular accident, transient ischemic attack, paroxysmal hypertension , vasculitis. Cough, difficulty breathing, nosebleed. Abdominal distention, altered bowel motility, peptic ulcer, dry mouth, gastrointestinal ulceration including gastrointestinal perforation and bleeding, pancreatitis, irritable bowel syndrome. Stevens-Johnson syndrome, toxic epidermal necrolysis, spasticity, muscle spasms, and musculoskeletal pain or stiffness. Proteinuria, increased serum creatinine, renal failure, impaired renal function. Increased Urea nitrogen in the blood, increased blood Creatin Phosphokinase, high blood potassium, increased uric acid. Rare: Angioedema, anaphylaxis, confusion, restlessness, hepatitis, liver failure, jaundice. Decreased blood sodium. Stop using Xibtosan after detecting the above side effects or any other abnormalities. Patients and family members should inform their doctor about the use of Xibtosan and immediately go to the nearest medical facility for timely treatment.
Notes on the use of Xibtosan in subjects
Care should be taken when using Xibtosan in patients with a history of or are suffering from diseases such as perforation, ulceration or gastrointestinal bleeding, risk of venous thromboembolism , severely impaired renal function. Pregnancy: There are no clinical data on the risk of Xibtosan in pregnant women. However, some studies indicate that drugs that inhibit prostaglandin synthesis should be avoided in the last months of pregnancy because they may cause premature closure of the ductus arteriosus. Therefore, caution should be exercised when using Xibtosan in pregnant women. Breast-feeding: Some studies have shown that the active ingredient Etoricoxib in Xibtosan can pass into breast milk, but the harmful effects of the drug on the infant are unknown. Therefore, avoid using Xibtosan in this population. Drivers or machine operators may experience neurological symptoms after taking Xibtosan.

Interaction with other drugs:
Combined use of Xibtosan and Warfarin can cause blood clotting disorders. Xibtosan reduces the effects of diuretics, angiotensin-converting enzyme (ACE) inhibitors and Angiotensin II antagonists (AIIAs). The combined use of Xibtosan and Aspirin increases the incidence of gastrointestinal ulcers and may increase the risk of side effects from Xibtosan. The combined use of Xibtosan and Cyclosporin or Tacrolimus may increase the nephrotoxic effect. Xibtosan reduces the renal excretion of Lithium or Methotrexate, thereby increasing the concentration of these active substances in the blood. Combined use of Xibtosan and oral contraceptives may increase the concentration of Ethinyl estradiol, thereby increasing the side effects of oral contraceptives. Xibtosan does not affect the pharmacodynamics of Prednisolone or Digoxin. Above is an overview of ingredients, usage and notes when using Xibtosan. In order to bring the best treatment results for themselves and their families, patients should carefully read the instructions for use of Xibtosan, and strictly follow the instructions of the specialist.